Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Kelley, R. K.; Negro, A.; Chen, C.; Ali, S.; Standifer, N.; Watras, M.; Evans, B.; Abou-Alfa, G. K. |
| Abstract Title: | Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | ESMO Immuno-Oncology Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2020 Dec 9-12 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-12-01 |
| Start Page: | S1429 |
| Language: | English |
| ACCESSION: | WOS:000600992500033 |
| DOI: | 10.1016/j.annonc.2020.10.519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 32P -- Source: Wos |
